Addex Therapeutics (ADXN)

Executive Summary

Addex Therapeutics is a clinical-stage biopharmaceutical company pioneering oral small molecule allosteric modulators for neurological disorders. Its lead candidate, dipraglurant, targets dyskinesia in Parkinson's disease and is being evaluated in a new Phase 2/3 trial following optimization of the formulation and dosing regimen. The company's collaboration with Janssen on ADX71149 for epilepsy, which has shown promising Phase 2 data, continues to advance with a planned pivotal study. Addex's proprietary allosteric modulator platform has also yielded earlier-stage candidates for depression, chronic cough, and neurodegenerative diseases. With a robust pipeline and strong partnership, Addex is positioned to address significant unmet needs in neurology.

Upcoming Catalysts (preview)

• Q1 2027Dipraglurant Phase 2/3 topline results in Parkinson's disease dyskinesia40% success
• Q3 2026ADX71149 pivotal trial initiation in epilepsy70% success
• TBDPotential partnership or licensing deal for early-stage pipeline candidate30% success